Pharmacological interventions for acute major depression and bipolar depression with mixed features: A systematic review and dose-related network meta-analysis across different age groups.
Michele Fornaro, Chiara Di Lorenzo, Nicolas Nunez et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and dose-related network meta-analysis compared pharmacological treatments with placebo or other treatments for acute bipolar depression and major depression with mixed features, including different age groups. It included 22 studies of 5,241 participants with bipolar depression and 13 studies of 1,814 with major depression. In bipolar depression, several doses of asenapine, lumateperone and lurasidone outperformed placebo for depressive symptom reduction; lurasidone-40 mg/day outperformed placebo in major depression (SMD = -0.80; 95% C.I. = -0.95, -0.65). Response benefits varied by drug and diagnosis.
Key findings
- For bipolar depressive symptoms, asenapine-15 mg/day, lumateperone-42 mg/day, and lurasidone-60 or 80 mg/day outperformed placebo in sensitivity analyses.
- In bipolar samples, cariprazine-1.5 or 3 mg/day, lurasidone-80 mg/day, and two olanzapine regimens outperformed placebo for response.
- For major depression with mixed features, lurasidone-40 mg/day reduced depressive symptoms versus placebo (SMD = -0.80; 95% C.I. = -0.95, -0.65); lumateperone-42 mg/day outperformed placebo for response (RR = 1.61; 95%C.I. = 1.20; 2.18).
- Larger efficacy and response effect sizes were associated with lower AMSTAR scores, indicating lower study quality.
Why it matters
Mixed-feature depression spans bipolar and major depressive diagnoses and age groups, and treatment estimates may differ across these populations and doses. This analysis brings comparative efficacy, response, acceptability, and evidence quality into one assessment, helping clinicians interpret drug-specific findings without assuming that results in one diagnostic group or age range apply to another.
What to keep in mind
The authors report that quantitative evidence for pharmacological management is relatively scant. Effect sizes were associated with study quality, with larger estimates linked to lower AMSTAR scores.